The continued solid uptake of Hims & Hers offerings and expanding subscriber base are likely to have driven the company's ...

Hims & Hers Health (NYSE:HIMS) recently announced a partnership with Novo Nordisk to enhance obesity care access in the U.S., coinciding with a notable 24% increase in its stock price over the last ...

SHOPPING: PSD underwear takes your style to the next level. Bold designs and unmatched comfort for a statement that starts ...

Hims & Hers launched a pharmacy-made weight-loss drug last year, taking advantage of an FDA rule allowing it to temporarily ...

Needham called the tie-up a “groundbreaking partnership” and said it alleviates investor concerns around Hims’ ability to hit ...

Wegovy, the popular weight-loss drug from Novo Nordisk, will be available through several leading telehealth providers, ...

Novo Nordisk is expanding access to its GLP-1 drug Wegovy via telehealth, partnering with Hims and Hers, Ro, and LifeMD.

After going after the companies making compounded versions of their drugs, GLP-1 makers are now going into business with the ...

Novo Nordisk has sought strength in numbers in the battle for telehealth obesity drug sales in the US, enlisting the aid of ...

Hims & Hers Health (NYSE: HIMS) stock surged 23% on Tuesday, April 29, after Novo Nordisk announced plans to offer popular ...

Drugmaker Novo Nordisk announced Tuesday that Wegovy will be available through telehealth providers. The providers -- Hims & ...

Novo Nordisk is partnering with online telehealth companies to sell a direct-to-consumer, lower cost version of its popular weight-loss drug Wegovy. The pharmaceutical company announced it would ...